Overview of Pfizer's Biosimilar Program

Pfizer received a Complete Response Letter from the FDA on 4/23/18 highlighting the need for additional technical information. Though this is a setback for Pfizer's Herceptin biosimilar program, there is no reason to believe that Pfizer won't be able to address the FDA's concerns and get the development program back on track.